A cute renal failure is a major and common complication of critically ill patients. Since it considerably affects their outcome, the major effort is to prevent its occurrence by adopting efficacious strategies when mild to moderate degrees of renal impairment, still amenable to renal protection, occur (1) . Renal hypoperfusion with ischemic injury accounts for 70% of all cases of acute renal failure (2) , and the maintenance of or increase in renal blood flow is considered crucial to favor the kidney oxygen supply/demand ratio and to prevent acute renal failure (3) .
"Renal-dose" dopamine has been frequently used in renal failure (4) , because in healthy volunteers low-dose dopamine increases renal blood flow and induces diuresis and natriuresis through the stimulation of dopamine (DA)-1 receptors (5, 6) . However, no consistent, substantial, and reproducible benefit has been proven in either preventing or treating acute renal failure (4) . The lack of any renoprotective effect was recently observed in early renal dysfunction in a broad group of critically ill patients (7) . Variable dopamine blood concentrations (8) with simultaneous stimulation of DA-1, DA-2 (9), and ␣1 receptors (10) have been reported within the kidney. DA-2 and ␣ stimulation decreases renal blood flow, glomerular filtration rate, and sodium excretion and may therefore offset any beneficial effect of DA-1 receptormediated vasodilation.
Fenoldopam mesylate is a selective DA-1 agonist, with no effects (even at high doses) on DA-2 and ␣1 receptors. In healthy subjects (11) , as well as in hypertensive patients (12, 13) , fenoldopam produces systemic and renal vasodilation. In healthy normotensive volunteers, fenoldopam increased renal blood flow in a dose-dependent manner with the great-est change in renal flow occurring between 0.03 and 0.1 g/kg/min (14) without any significant reduction in systemic arterial pressure. The selective renal vasodilation may provide a potential benefit in preserving kidney function, but data regarding its clinical efficacy in acute renal damage are still scarce (15) . Fenoldopam seems to exert a renoprotective effect when administered prophylactically in patients undergoing elective aortic surgery (16, 17) or cardiopulmonary bypass (18) . Moreover, fenoldopam seems to preserve renal function by counterbalancing the renal vasoconstrictive effects of cyclosporine in kidney (19) and liver (20) transplant patients. The effects of fenoldopam administration in patients at high risk of radiographic contrast nephropathy are controversial. Although some authors have suggested that fenoldopam may be a promising prophylactic agent for radiographic contrast nephropathy (21, 22) , others have not confirmed its efficacy (23) .
No data exist regarding the potential role of fenoldopam as a nephroprotective agent in critically ill patients. In the setting of renal dysfunction, when a moderate impairment may be still amenable to reversal, a selective renal vasodilator such as fenoldopam could counterbalance any renal hypoperfusion and prevent acute renal failure.
The aim of the present study was to compare fenoldopam and low-dose dopamine as renoprotective agents in early acute renal dysfunction of critically ill patients.
METHODS
Between August 2001 and May 2003, all the patients admitted to the four participating intensive care units (ICUs) were screened to identify adult patients meeting the following inclusion criteria: age Ͼ18 yrs; ICU stay Ͻ1 wk; hemodynamic stability (defined as stable values of systolic blood pressure Ն100 mm Hg over the 6-hr period immediately preceding enrollment; low doses of vasopressors were allowed); life expectancy Ͼ48 hrs; and at least one of the following indicators of early renal dysfunction: urine output Յ0.5 mL/kg over a 6-hr period and serum creatinine concentration Ն1.5 mg/dL and Յ3.5 mg/dL in absence of rhabdomyolysis and myoglobinuria.
Exclusion criteria were a different episode of acute renal failure within the previous 3 months, obstructive renal dysfunction, premorbid renal dysfunction requiring chronic hemodialysis or peritoneal dialysis, and unsuitability for use of any kind of renal replacement therapy.
The study protocol was approved by each local institutional ethics committee. Patients or their next of kin gave informed consent to participate in the trial.
Patients were assigned by randomization (sealed envelope) to study groups. The study medications were diluted and prepared for 50-mL pump syringes in order to be infused to yield 2 g/kg/min dopamine (group D) or 0.1 g/kg/min fenoldopam mesylate (group F).
Drug infusion was continued for a maximum of 4 days or until one of the following events occurred, whichever came first: the patient died, renal dysfunction resolved for Ն48 hrs, the patient was discharged from ICU, the patient was given any kind of renal replacement therapy (for volume overload and/or hyperkalemia and/or severe acidosis), or a serious adverse event potentially related to drug infusion occurred.
Each patient's age, gender, weight, diagnostic category (medical, surgical, trauma), comorbidities, Acute Physiology and Chronic Health Evaluation II, and Simplified Acute Physiology Score II at ICU admission were collected. At enrollment, risk factors for acute renal dysfunction were recorded as well as the presence of systemic inflammatory response syndrome and sepsis according to standard criteria (24) . Arterial pressure (systolic, diastolic, and mean), heart rate, body temperature, ventilator status, arterial blood gas analysis, serum creatinine, blood urea nitrogen, and routine chemical blood analysis were collected at baseline (T0). Moreover, Acute Physiology and Chronic Health Evaluation II, Simplified Acute Physiology Score II, Sequential Organ Failure Assessment score, and extrarenal Sequential Organ Failure Assessment score (calculated by adding all the single organ dysfunction scores with exception of renal score) of the 24 hrs immediately preceding the enrollment were calculated. Urine output and fluid intake over the 24 hrs (when available), 6 hrs, and 1 hr before start of infusion were measured. Use and dose of any vasoactive agent and diuretic in the previous 24 hrs, and use of nephrotoxic drugs or substances in the previous 3 days, were also recorded. Drugs or substances considered as nephrotoxic were aminoglycosides, vancomycin, radiocontrast agents, amphotericin B, nonsteroidal antiinflammatory drugs, and cyclosporine.
During the study period, arterial blood pressure and heart rate were collected 2, 6, and 12 hrs after start of infusion and each day at the same time over the whole infusion period. Creatinine and all other blood variables were measured daily over the whole infusion period (first day, T1; second day, T2; third day, T3; fourth day, T4). Sequential Organ Failure Assessment score was calculated each day as well as ventilator status and arterial blood gas analysis. Urine output and fluid intake were recorded from the start of infusion to the time of the following day corresponding to blood pressure measurement and blood sampling (T1). In the next days, urine output and fluid intake data were collected at the same time. For this reason, although the time interval between the start of infusion and T1 could be Ͻ24 hrs, the time intervals between T1 and T2, T2 and T3, T3 and T4 correspond to a 24-hr period. Prescription of drugs affecting urine output or glomerular filtration rate and of vasoactive agents was not controlled but was recorded during the study period. Creatinine measurements were accomplished in a single laboratory for each patient with the alkaline picric acid (Jaffe) method. In all laboratories daily intralaboratory and bimonthly interlaboratory quality controls were performed, and the reported bias of the instruments used in creatinine measurement was Յ0.11 mg/dL (25) . Creatinine clearance was calculated by the Cockcroft and Gault formula (26) .
The primary end point was the change in serum creatinine values over time. In each patient, creatinine absolute and relative (Ͼ10%) changes from baseline were evaluated. Secondary end points were changes in arterial blood pressure, the occurrence of acute renal failure, the need for renal replacement therapy, daily urine output, and use of diuretics.
Statistical Analysis. Data are expressed as mean Ϯ SD, unless otherwise specified. For statistical analysis, only patients who completed Ն48 hrs of drug infusion were included. Since a pretrial observational study showed that with the established inclusion criteria the basal mean value of the creatinine was 2.2 mg/dL with an SD equal to 20% of its mean, for the trial to have 80% power of detecting a 10% decrease in serum creatinine with fenoldopam, at ␣ ϭ .05, we calculated that 50 patients would be needed.
Data distribution was tested for normality before analysis. The two groups were compared by using unpaired Student's t-test or Mann-Whitney U test for continuous variables, and chi-square test was applied for categorical ones. Continuous data with asymmetric distribution (creatinine, creatinine clearance, and urea) were shifted to normal distribution after natural logarithmic transformation; therefore, analysis was performed with a parametric twoway analysis of variance for repeated measures and described after back-transformation. To assess the effects of drugs and time on creatinine, blood urea, creatinine clearance, diuresis, fluid intake, and hemodynamic variables, a model with drug, time, time-drug interaction, and nested effect of subject within drug was performed. The p value for multiple comparisons between drugs at each time was adjusted with bootstrap method. Analysis was performed with SAS version 8.2 PROC GLM (SAS Institute, Cary, NC), which performs multivariate general linear model analysis for repeated measures with analysis of profile and contrast of each time with baseline. We considered p Ͻ .05 to be statistically significant.
RESULTS
A total of 110 patients were enrolled in the study. Most of patients were enrolled in a single center (n ϭ 86). Eight patients did not meet inclusion criteria (serum creatinine values were in one patient Ͼ3.5 mg/dL and in one Ͻ1.5 mg/dL, one patient had myoglobinuria, four patients had a life expectancy Ͻ48 hrs, one patient became hemodynamically unstable after enrollment and before start of infusion) and did not start the trial, whereas two patients were discharged from ICU the day after enrollment and could not complete the minimum 48-hr period of drug infusion. After exclusion, 100 patients were included in the analysis. Both dopamine (D) and fenoldopam (F) groups included 50 patients.
Demographic and clinical characteristics of patients included in the analysis are given in Table 1 . The two groups were well matched at admission to ICU for age, gender, illness severity, clinical characteristics, and creatinine value.
Mean interval between ICU admission and start of infusion was 41.1 Ϯ 38 hrs in the dopamine group and 34.6 Ϯ 36.6 hrs in the fenoldopam group (p ϭ .38). Patients' clinical characteristics at start of infusion are summarized in Table 2 (Table 2) . Oliguria was present in seven patients of the fenoldopam group and six patients of the dopamine group (not significant).
After randomization, dopamine was infused for a mean of 82.8 Ϯ 16 hrs and fenoldopam for 84.2 Ϯ 12 hrs (p ϭ .61). The mean time between start of infusion (T0) and T1 was 16 Ϯ 3.3 hrs in group F and 16.1 Ϯ 4.1 hrs in group D (p ϭ .87). Five patients in group F and six patients in group D did not complete the 4-day period of infusion. In group F, two patients were discharged from ICU after T3 and two patients were discharged after T2. One patient was treated with renal replacement therapy and infusion was stopped. In group D, five patients were discharged from ICU after T2, and one patient died during the study (acute on chronic respiratory failure).
At baseline, systolic arterial pressure was 131.3 Ϯ 19 and 131 Ϯ 16.7 mm Hg, diastolic arterial pressure was 67.4 Ϯ 14.1 and 67.4 Ϯ 11.3 mm Hg, and mean arterial pressure was 88.5 Ϯ 13.2 and 87 Ϯ 15.5 mm Hg in groups F and D, respectively. Heart rate was 87.3 Ϯ 15.9 and 89.6 Ϯ 18 beats/min in groups F and D, respectively (not significant). General linear model analysis showed no difference in heart rate and systolic, diastolic, and mean systemic arterial pressure between groups during infusion (Fig. 1) . Globally, over time a significant difference was observed in systolic arterial pressure (F ϭ 3.1, p ϭ .009) and heart rate (F ϭ 3.39, p ϭ .005). Systolic arterial pressure after 2 hrs was lower than baseline (F ϭ 10.4, p ϭ .002) and at T1 was lower than after 12 hrs (F ϭ 12.2, p ϭ .001); heart rate at T2 was lower than T1 (F ϭ 7.2, p ϭ .009, Fig. 1) . No interaction between time and drugs was observed for any hemodynamic variable.
The number of episodes of systolic blood pressure measurements Ͻ100 mm Hg was calculated over the entire period of drug infusion and normalized to the total number of pressure measurements. No significant difference was observed (6 Ϯ 11% vs. 5.2 Ϯ 8 % in groups F and D, respectively, p ϭ .66).
Mean values of creatinine, creatinine clearance, and blood urea in both groups are shown in Table 3 . For serum creatinine concentrations, general linear model analysis showed no difference between groups but a significant effect of time (F ϭ 11.2, p Ͻ .0001) and of interaction (time ϫ drug, F ϭ 3.7, p ϭ .03). Globally, differences were observed between T2 and T1 (F ϭ 13.2, p ϭ .0005) and between T3 and T2 (F ϭ 9.7, p ϭ .0025). No difference in creatinine reduction from T0 to T1 between drugs was observed (F ϭ 4.92, p ϭ .03, p adjusted ϭ .44). Significant differences between drugs were observed in creatinine reduction from T0 to T2 (F ϭ 6.4, p ϭ .01, p adjusted ϭ 0.047), from T0 to T3 (F ϭ 5.9, p ϭ .01, p adjusted ϭ 0.047), and from T0 to T4 (F ϭ 4.51, p ϭ .036; p adjusted ϭ 0.02, Fig. 2) .
No difference was found in peak creatinine and in maximum increase in creatinine compared with baseline during the study period between groups F and D (Table 4 ). The absolute variations in creatinine value between baseline and the last measured value showed a significant difference between groups (Table 4 ). In the fenoldopam group, at the end of infusion, creatinine had decreased by 0.29 Ϯ 0.77 mg/dL, a value significantly different than the dopamine group (0.09 Ϯ 0.94 mg/dL, p ϭ .03, Table 4 ). Maximum decrease in creatinine compared with baseline was significantly greater in F than group D (p ϭ .027, Table 4 ).
Sixty-six percent of patients in the fenoldopam group had a creatinine de- crease Ͼ10% of the baseline value at the end of infusion compared with only 46% in dopamine group (chi-square ϭ 4.06, p ϭ .04, Table 4 ). In 16 patients in the dopamine group and in 25 patients in the fenoldopam group, creatinine values were Ͻ1.5 mg/dL at end of infusion (chi-square ϭ 3.35, p ϭ .067). The number of patients with creatinine values Ͼ3.5 mg/dL at the end of infusion was not different between groups (three in group F and six in group D, p ϭ .24). Renal replacement therapy was deemed necessary in a total of five patients, three in group D and two in group F (Table 4) . For creatinine clearance, general linear model analysis showed no difference between groups but a significant effect of time (F ϭ 11.1, p Ͻ .0001) and of interaction (time ϫ drug, F ϭ 3.7, p ϭ .03). Differences were observed between T2 and T1 (F ϭ 13.2, p ϭ .0005) and between T3 and T2 (F ϭ 9.7, p ϭ .0025). Creatinine clearance variation from T0 to T1 was not different between drugs (F ϭ 5, p ϭ .027, p adjusted ϭ 0.43). Significant differences between drugs were observed in a creatinine clearance increase from T0 to T2 (F ϭ 6.5, p ϭ .01, p adjusted ϭ 0.045), from T0 to T3 (F ϭ 5.9, p ϭ .01, p adjusted ϭ 0.046), and from T0 to T4 (F ϭ 4.56, p ϭ .036, p adjusted ϭ 0.02).
For blood urea, general linear model analysis showed no effect of drugs, time, and interaction.
Urinary output was not different before the start of infusion between groups. In the 6 hrs immediately preceding the start of infusion, mean urinary output was 1.52 Ϯ 0.93 mL/kg/hr in group F and 1.61 Ϯ 1.12 mL/kg/hr in group D (p ϭ .67). Seven patients in group F and six patients in group D had diuresis Յ0.5 mL/kg/hr. No significant effect of time or drugs was observed in urine output (Fig.  3) . At T1, a significant difference was observed between groups D and F: Mean urinary output of group F was significantly lower than group D (1.28 Ϯ 0.68 vs. 1.72 Ϯ 0.99 mL/kg/hr, respectively, F ϭ 4.5, p ϭ .037, Fig. 3 ).
Fluid intake was not different between groups. In the 6 hrs before start of infusion, fenoldopam patients received a mean of 2.1 Ϯ 1.6 mL/kg/hr of fluids and dopamine patients received 1.9 Ϯ 1.3 mL/kg/hr (p ϭ .54). During the trial, no difference was observed between groups in mean daily (Fig. 3) and cumulative (Table 5 ) fluid intake.
In the 24 hrs preceding enrollment, furosemide was administered in 35 patients of the dopamine group and 32 patients of the fenoldopam group. Mean total dose of furosemide administered as bolus injection or continuous infusion within the study period was 305 Ϯ 478 mg and 278 Ϯ 503 mg in D and F patients, respectively (p ϭ .79). Osmotic diuretics were administered in 12 patients of each group before enrollment and in 12 D patients and 13 F patients during the trial. In the time frame T0 -T1, mean dosage of furosemide was 67.7 Ϯ 118 mg and 59.4 Ϯ 107.3 mg in groups D and F, respectively (p ϭ .71). During the trial, one patient of group F and three patients of group D received spironolactone, and one patient in group D received ethacrynic acid. There was no significant difference in the number and type of vasoactive agents and nephrotoxic substances administered during infusion (Table 5) .
Total extrarenal Sequential Organ Failure Assessment score was similar in the two groups at the end of infusion (5.8 Ϯ 3.6 vs. 5.6 Ϯ 4 in groups F and D, respectively, p ϭ .79).
DISCUSSION
A continuous infusion of fenoldopam at 0.1 g/kg/min does not cause any significant hemodynamic impairment and improves renal function. Fenoldopam administration is associated with a greater decrease in serum creatinine values as well as with a higher number of patients with improved renal function compared with low-dose dopamine. Therefore, in early acute renal dysfunction of critically ill patients, fenoldopam seems to be superior to low-dose dopamine as a renoprotective agent.
Some methodological issues require a more detailed analysis. The fenoldopam dose (0.1 g/kg/min) was chosen to produce renal effects without any systemic effects on the basis of doseresponse characteristics in clinical settings different from critically ill patients. Fenoldopam produces a selective renal vasodilation at 0.03 g/kg/min, and the greatest increase in renal blood flow is observed between 0.03 and 0.1 g/kg/min. In an experimental setting by using a dose-finding regimen, no significant decrease in blood pressure was observed during infusion of fenoldopam at 0.1 g/kg/min (27) . This is consistent with the findings of Murphy et al. (28) , who observed a Ͼ10 mm Hg reduction of diastolic blood pressure only in one of 17 patients with essential hypertension. Moreover, a dose of 0.1 g/kg/min and even higher (0.3 g/kg/min) does not affect systolic blood pressure and only minimally decreases diastolic pressure in normotensive individuals, due to the lesser role that resistance vessels play in determining blood pressure in such patients (14) . However, it was not possible to exclude a priori a potential hypotensive effect of fenoldopam in critically ill patients, and the present study was, therefore, not double-blind.
No significant difference in systemic blood pressure was observed between fenoldopam at 0.1 g/kg/min and lowdose dopamine. Systolic pressure tended to decrease after the start of both drug infusions, but this reduction was not clinically significant. The number of hypotensive episodes (systolic blood pressure Ͻ100 mmHg) during trial infusion was not significantly different between groups, and there was no difference in the number of patients requiring vasoactive drug infusion during the trial. Therefore, an infusion of 0.1 g/kg/min fenoldopam in critically ill, hemodynamic stable patients does not produce any significant hypotensive effect that would outweigh the benefits derived from a selective renal vasodilation.
The rise in serum creatinine lags behind the process leading to acute renal failure, and its reduction lags behind an improvement in renal function. A very recent study reported a beneficial effect of fenoldopam in liver transplant recipients after 72 hrs of infusion (20) . Therefore, the 4-day infusion was considered sufficient to give both drugs a chance to produce an appreciable clinical effect. The general linear model analysis, although it did not show a significant difference between groups in creatinine concentration and clearance, evidenced a significant difference in creatinine reduction between drugs; that is, the profiles of variations were different between dopamine and fenoldopam. As a matter of fact, the analysis of changes in creatinine and creatinine clearance values between baseline and each time point showed that fenoldopam was more effective than dopamine after almost 2 days of infusion. Moreover, the maximum decrease in creatinine, compared with baseline, evidenced a greater improvement in renal function during fenoldopam administration. The individual analysis of creatinine variations confirmed a significant, more pronounced beneficial effect of fenoldopam on renal function, compared with dopamine.
Another methodological issue is represented by the choice of low-dose dopamine for the control group. Although renal-dose dopamine has been frequently used in renal failure, no consistent, substantial, and reproducible benefit has been proven (4). In a multiple-center, randomized, placebo-controlled study performed in critically ill patients with systemic inflammatory response and early renal dysfunction, low-dose dopamine did not result in any difference in renal recovery and peak serum creatinine compared with placebo (7). However, as evidenced by a recent meta-analysis (29), dopamine does not appear to increase the risk of death, acute renal failure, or hemodialysis and seems to be a relatively safe agent, although ineffective for preventing or treating renal dysfunction. The lack of any dopamine-related renoprotective effect may be explained by the wide variability in action across patients and clinical conditions and by the difficulty of predictably activating only the DA-1 receptors. On the contrary, fenoldopam, as a selective agonist of peripheral and renal DA-1 receptor, is six times more effective as a renal vasodilator than dopamine and causes no activation of other adrenergic receptors (30) . In the present study, the predisposing factors for renal dysfunction were those usually associated with renal impairment in the ICU setting. Renal dysfunction in the context of a multiple organ dysfunction was related in almost 25% of patients to a preceding shock episode, in 30% of patients to sepsis, and in 50% of patients to administration of nephrotoxic substances. Moreover, most of patients had a preexisting chronic disease potentially inducing renal microangiopathy. The combination of all these factors is able to induce vasoconstriction and hypoperfusion with renal ischemia, known as the most common cause of acute renal dysfunction (31) . In this context, the reversal of an often clinically unapparent vasoconstriction potentially contributing to renal dysfunction may be preferable to an attempt to intervene after severe renal failure has occurred (32) . The greatest risk of ischemic injury involves the medullary portion of the nephrons, with high oxygen demand (due to tubular transport activity) but receiving only 5% of total renal blood flow. Medullary oxygen extraction approaches 90% (31) , and cells are in a constant low-oxygen environment. Although any increase in renal flow by dopamine is not necessarily associated with an improvement in renal medullary dysoxia (33) , fenoldopam is reported to increase both medullary and cortical blood flows-with a trend favoring a larger increase in medullary over cortical blood flow (34)-and to reduce the oxygen demand of this region by inhibiting sodium transport in the medullary thick ascending limb (35) . Moreover, the direct stimulation of DA-1 receptors inhibits Na ϩ K ϩ -adenosine triphosphatase activity, reduces ionic transport (i.e., sodium readsorption), and may decrease oxygen consumption within the proximal convoluted tubules (36) and the cortical collecting duct (37) . Recently, it has been demonstrated that in stable critically ill patients, fenoldopam favorably affects the balance between renal oxygen supply and demand as evidenced by the dose-dependent increase in urinary oxygen tension, unrelated to indexes of systemic perfusion and cardiac function (38) . Therefore, a more powerful and selective DA-1 stimulation with renal vasodilation improves oxygen balance in the kidney and may explain why fenoldopam is more effective than low-dose dopamine in reducing serum creatinine values.
In the present study, no significant change in urinary output after fenoldopam infusion was observed, confirming the variability of fenoldopam effects on urine output. In hypertensive patients, fenoldopam increases renal flow, glomerular filtration rate (suggesting a greater vasodilation of the afferent arteriole), and diuresis (12) . However, in experimental models, fenoldopam increases renal blood flow more than glomerular filtration rate, as the result of a preferential efferent arteriolar vasodilation, with a reduction in glomerular ultrafiltration pressure (39) . This behavior is observed in normotensive subjects in whom 0.1 g/kg/min fenoldopam increases renal blood flow more than glomerular filtration rate, with no change in urine volume (14) . Similarly, in critically ill patients under mechanical ventilation with positive endexpiratory pressure, the administration of 0.1 g/kg/min fenoldopam decreased renal vascular resistance but did not change urine flow rate, which increased only by higher doses (40) . At T1 (i.e., after Ͻ1 day of infusion), urine output with dopamine was significantly higher than with fenoldopam. This difference vanished after T1, and the mean urinary output during the whole trial infusion was not different between groups. Prescription of drugs affecting urine output or glomerular filtration rate, such as loop diuretics and mannitol, was not controlled, because our purpose was to test the effect of fenoldopam in a clinical environment that was representative of current practice. However, the mean and daily amount of diuretics was not different in fenoldopam and dopamine groups. Therefore, diuretics cannot explain this result. Systemic hemodynamics as well as fluid intake in the hours immediately preceding enrollment were not different between groups. Moreover, both groups received the same daily and cumulative amount of fluids during drug infusion. Therefore, differences in intravascular filling are unlikely to explain the different effects of fenoldopam and dopamine on renal function and diuresis. The most likely explanation is that in the first hours of infusion, dopamine exerts a more marked diuretic effect than fenoldopam, confirming that the main consistent effect of low-dose dopamine in critically ill patients is promoting diuresis. This dopamine-related diuretic effect seems to wane over time, as confirmed by others (41) .
CONCLUSIONS
A continuous infusion of fenoldopam at 0.1 g/kg/min is able to improve renal function, compared with renaldose dopamine. Since no change in serum creatinine level, however small, can be considered inconsequential (42) , and since even minor alterations in renal function can cause excess mortality, independent of other factors (43) , the improvement in early renal dysfunction might provide substantial benefits for critically ill patients. Fenoldopam may help prevent the progression to wellestablished acute renal failure or accelerate the recovery of renal function in critically ill patients. Further studies are necessary to investigate if this promising effect would lead to a reduction in morbidity and possibly mortality rates and in the cost of medical care.
